New drug aims to tackle two conditions at once: heart disease and erectile dysfunction
NCT ID NCT07311330
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called YN001 in 40 people who have both atherosclerotic cardiovascular disease (hardening of the arteries) and erectile dysfunction. The trial is double-blind and placebo-controlled, meaning neither patients nor doctors know who gets the real drug. The goal is to see if YN001 improves erectile function and reduces artery thickness over 13 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fenugreek extract put to the test as a natural remedy for erectile dysfunction
- Erectile dysfunction may be an early warning for heart trouble in men with hypertension
- Can adjusting drug schedules improve both urinary and sexual outcomes in men with enlarged prostate?
- Could cialis go over the counter? new study tests safe access without a prescription
- New pill could help men with erectile dysfunction achieve and maintain erections
- Talking about sex after cancer: telehealth therapy may improve recovery